# NCT04607421 (NCT04607421)

> A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04607421
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Neoplasms
- Interventions: Encorafenib; Cetuximab; Oxaliplatin; Irinotecan; Leucovorin; 5-FU; Capecitabine; Bevacizumab
- Enrollment: 841
- Primary outcome: SLI: Number of Participants With Dose Limiting Toxicity (DLTs)
- Primary outcome: Phase 3: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) for Arm B vs Arm C - FAS
- Primary outcome: Phase 3: Objective Response Rate (ORR) as Assessed by BICR for Arm B vs Arm C - FAS ORR Subset
- Primary outcome: Cohort 3: ORR as Assessed by BICR for Arm D vs Arm E - FAS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04607421